Loading...
•
Sep 30, 2023
Puma Biotechnology Q3 2023 Earnings Report
Puma Biotechnology reported positive net income and positive cash flow.
Key Takeaways
Puma Biotechnology announced its Q3 2023 financial results, with a net income of $5.8 million, or $0.12 per basic and diluted share, compared to a net loss of $0.4 million in Q3 2022. Total revenue was $56.1 million, including $51.6 million from product revenue and $4.5 million from royalty revenue.
Puma Biotechnology reported a net income of $5.8 million, or $0.12 per basic and diluted share.
Non-GAAP adjusted net income was $8.3 million, or $0.18 per basic share and $0.17 per diluted share.
Total revenue was $56.1 million, including $51.6 million from product revenue and $4.5 million from royalty revenue.
Net cash provided by operating activities was $10.7 million.
Revenue by Segment
Forward Guidance
Puma Biotechnology anticipates product revenue between $56 million and $59 million and royalty revenue between $16 million and $19 million for the fourth quarter of 2023. Net income is expected to be between $13 million and $16 million.
Positive Outlook
- Product Revenue, Net: $56 million - $59 million
- Royalty Revenue: $16 million - $19 million
- Net Income: $13 million - $16 million
- Full Year 2023 Product Revenue, Net: $206 million - $209 million
- Full Year 2023 Royalty Revenue: $30 million - $32 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...